Oncology

A phase 1–2 clinical trial found that adagrasib combined with cetuximab in patients with KRAS G12C mutations can increase progression-free survival and overall survival in refractory colorectal cancer patients. There is a pressing need for effective treatments for metastatic colorectal cancer, particularly for patients with the KRAS G12C mutation, a kind of colorectal cancer that...

A phase 3 clinical trial confirms that combination therapy with trifluridine–tipiracil plus bevacizumab is associated with better clinical outcomes in refractory colorectal cancer cases than trifluridine–tipiracil monotherapy. First-line and second-line treatment of colorectal cancer includes chemotherapy with fluorouracil-based agents (oxaliplatin and irinotecan) along with newer vascular endothelial growth factor (VEGF)-based therapy (mainly bevacizumab) and epidermal...

Reductions in cancer mortality being threatened by increasing incidence for six of top 10 cancers Cancer mortality is decreasing, but progress is being hampered by increasing incidence of some cancers, according to a study published online Jan. 17 in CA: A Cancer Journal for Clinicians. Rebecca L. Siegel, M.P.H., from the American Cancer Society in Atlanta,...

Beta-sitosterol supplements seem to be most appropriate for younger men with minimal symptoms who wish to avoid clinical drug regimens for benign prostatic hyperplasia treatment, according to the findings of a recent literature review. Herbal supplements containing plant sterols, vitamins, and minerals are widely used to enhance prostate health. Beta-sitosterol often forms the most abundant...

Radiomics models based on automatic segmentation of pretreatment apparent diffusion coefficient maps showed promise for predicting the biochemical recurrence of advanced prostate cancer in a recent study. Many prostate cancer (PCa) patients experience biochemical recurrence (BCR) during treatment. Early BCR detection is essential for timely intervention to limit disease progression and improve survival. Radiomics is...

The presence of multifocal positive surgical margins after robotic radical prostatectomy was associated with mortality in patients with adverse clinical and pathological characteristics in a retrospective cohort study. Positive surgical margins (PSMs) represent an adverse feature in prostate cancer patients undergoing radical prostatectomy (RP). PSMs are common post-RP and found in 6–40% of patients. Although...

Aberrant expression of various glycolytic enzyme genes is significantly associated with prostate cancer progression and survival outcomes, according to a recent systematic analysis. Prostate cancer (PCa) is the second-leading cause of cancer death in men. Recent studies showed that alterations in metabolic pathways are involved in PCa development and progression.  A study in the American...

Transperitoneal and extraperitoneal approaches to three-dimensional laparoscopic radical prostatectomy have similar clinical outcomes, according to a recent retrospective study. Radical prostatectomy is among the best treatments for localized prostate cancer. Three-dimensional laparoscopic radical prostatectomy (3D LRP) has two main surgical approaches, namely 3D extraperitoneal LRP (3D ELRP) and 3D transperitoneal LRP (3D TLRP). There is...

The fatty acid-binding protein 5 inhibitor SBFI-103 can potentially eliminate drug-resistant prostate cancer cells at a well-tolerated dose. Prostate cancer (PCa) treatment faces challenges due to the lack of effective targets, as initial success with androgen receptor blockade gives way to drug resistance and lethal relapse of the disease. Research has shown that lethal recurrent...